Pfizer has signed a research collaboration and license agreement with Enodia Therapeutics to discover and develop small-molecule Sec61 inhibitors, in a deal potentially worth more than $500 million. Enodia will lead discovery against multiple targets using its selective Sec61 translocon modulation platform, while Pfizer takes over clinical, manufacturing, regulatory and commercial work.

Why It Matters To Oncology

• Sec61 is an emerging target for modulating the production of disease-driving proteins, offering a small-molecule route to suppress hard-to-drug oncology targets at the protein translocation step.

• Enodia says its platform is designed to achieve selective Sec61 modulation, with the goal of inhibiting pathological proteins while preserving essential physiological functions — a key challenge for this target class.

• For clinicians tracking drug discovery, the collaboration signals continued pharma interest in upstream protein-targeting approaches beyond classic kinase inhibition, antibodies and targeted protein degradation.

The Financials

• The deal is potentially worth over $500 million.

• Enodia will receive an undisclosed upfront payment, and is eligible for downstream development and commercial milestone payments.

• The biotech is also in line for tiered sales royalties if partnered products reach market.

What They're Saying

• CEO Yves Ribeill called selective Sec61 translocon modulation “a novel approach to inhibit disease-driving proteins while preserving essential physiological functions.”

• Ribeill said the company aims to pair Pfizer’s development and clinical scale with Enodia’s precision approach to targeting pathological proteins.

What's Next

• Enodia will screen, optimize and advance Sec61 inhibitor candidates across multiple collaboration targets.

• Pfizer will assume responsibility for clinical development, manufacturing, regulatory filings and commercialization after the discovery phase.

• Watch for which tumor-relevant targets emerge from the collaboration, and whether selective Sec61 inhibition can show a therapeutic window broad enough for oncology development.